The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%.
SNVs and indels (969 mutations across these 44 genes): AKT1, ALK, APC, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SF3B1, SMAD4, SMO, and TP53.
NOTE: Not available for samples from New York.
Liquid biopsy (also called plasma testing) is appropriate for situations when tissue is insufficient, unavailable, or not practical to obtain, or when results are needed more quickly than they can be obtained from tissue analysis. The NeoLAB® Solid Tumor Liquid Biopsy includes targets significant to a wide variety of solid tumors including colorectal, pancreas, prostate, melanoma, head & neck, bladder, thyroid, kidney, ovarian, liver, thyroid, breast*, and lung*. Tissue testing is recommended over plasma testing when possible.
*See also our other liquid biopsy InVisionFirst®-Lung for lung.
- Peripheral blood: two x 10 mL Streck Cell-Free DNA BCT® tubes
Do not refrigerate. Request collection kits from Client Services and see collection and shipping instructions here (also included in kit).